N. Kojima et al. / Bioorg. Med. Chem. Lett. 19 (2009) 2144–2147
2147
941; (b) Kojima, N.; Sugino, M.; Mikami, A.; Nonaka, K.; Fujinawa, Y.; Muto, I.;
Matsubara, K.; Ohtsuka, E.; Komatsu, Y. Bioorg. Med. Chem. Lett. 2006, 16, 5118.
6. The Glen Reports, 2007, 19, 6.
7. Tetzlaff, C. N.; Schwope, I.; Bleczinski, C. F.; Steinberg, J. A.; Richert, C.
Tetrahedron Lett. 1998, 39, 4215.
measurements. This work was supported financially by the
National Institute of Advanced Industrial Science and Technology
(AIST).
8. Ocampo, S. M.; Albericio, F.; Fernández, I.; Vilaseca, I.; Eritja, R. Org. Lett. 2005,
7, 4349.
Supplementary data
9. Zaramella, S.; Yeheskiely, E.; Strömberg, R. J. Am. Chem. Soc. 2004, 126, 14029.
10. The 50-amino-modified ONTs on the CPG-support (0.1
lmol) were treated with
Detailed experimental protocols of the solid-phase conjuga-
tion reactions, list of results, and HPLC chromatograms of the
reactions. Supplementary data associated with this article can
N-Fmoc-Phe (10 equiv), the coupling reagent (10 equiv) and DIEA (20 equiv) in
DMF (0.5 mL), or N-Fmoc-Phe-OPfp ester (10 equiv) and DIEA (20 equiv) in
DMF (0.5 mL). See the Supplementary data for more details.
11. The products were confirmed by MALDI-TOF/MS measurements. See the
Supplementary data.
12. (a) Wolfrum, C.; Shi, S.; Jayaprakash, K. N.; Jayaraman, M.; Wang, G.; Pandey, R.
K.; Rajeev, K. G.; Nakayama, T.; Charrise, K.; Ndungo, E. M.; Zimmermann, T.;
Koteliansky, V.; Manoharan, M.; Stoffel, M. Nat. Biotechnol. 2007, 25, 1149; (b)
Lorenz, C.; Hadwiger, P.; John, M.; Vornlocher, H.-P.; Unverzagt, C. Bioorg. Med.
Chem. Lett. 2004, 14, 4975.
References and notes
13. The 50-amino-modified ONTs on the CPG-support (0.1
lmol) were treated with
1. (a) Manoharan, M. Curr. Opin. Chem. Biol. 2004, 8, 570; (b) Bijsterbosch, M. K.;
Rump, E. T.; De Vrueh, R. L. A.; Dorland, R.; van Veghel, R.; Tivel, K. L.; Biessen, E.
A. L.; van Berkel, T. J. C.; Manoharan, M. Nucleic Acids Res. 2000, 28, 2717; (c)
Letsinger, R. L.; Zhang, G.; Sun, D. K.; Ikeuchi, T.; Sarin, P. S. Proc. Natl. Acad. Sci.
U.S.A. 1989, 86, 6553.
cholesteryl chloroformate (40 equiv) and DIEA (80 equiv for X-T15, 20 equiv
for X-25) in dichloromethane (0.5 mL) at room temperature for 15 min. See the
Supplementary data for more details. The longer ONTs were used in the
cholesterol coupling reactions for the purpose of increasing the solubility of the
chol-ONT conjugates in water.
2. (a) Venkatesan, N.; Kim, B. H. Chem. Rev. 2006, 106, 3712; (b) Tung, C.-H.
Bioconjugate Chem. 2000, 11, 605.
14. The 50-amino-modified ONTs on the CPG-support (0.1
lmol) were treated with
cholesteryl chloroformate (40 equiv), DMAP (20 equiv) and DIEA (20 equiv) in
dichloromethane (0.5 mL) at room temperature for 15 min. See the
Supplementary data for details.
3. (a) Zatsepin, T. S.; Stetsenko, D. A.; Gait, M. J.; Oretskaya, T. S. Bioconjugate
Chem. 2005, 16, 471; (b) Virta, P.; Katajisto, J.; Niittymäki, T.; Lönnberg, H.
Tetrahedron 2003, 59, 5137.
4. (a) Bologna, J.-C.; Imbach, J.-L.; Morvan, F. Tetrahedron Lett. 2000, 41, 7317; (b)
Gryaznov, S. M.; Lloyd, D. H. Nucleic Acids Res. 1993, 21, 5909.
5. (a) Komatsu, Y.; Kojima, N.; Sugino, M.; Mikami, A.; Nonaka, K.; Fujinawa, Y.;
Sugimoto, T.; Sato, K.; Matsubara, K.; Ohtsuka, E. Bioorg. Med. Chem. 2008, 16,
15. The 50-amino-modified ONT on the CPG-support (0.1
lmol) was treated with
cholesteryl chloroformate (150 equiv), DMAP (20 equiv) and DIEA (20 equiv) in
dichloromethane (0.5 mL) at room temperature for 5 min. See the
Supplementary data for details.